Valued at USD 5.60 billion in 2024, the global neurology clinical trials market is projected to reach USD 5.96 billion in 2025 and USD 10.59 billion by 2034, growing at a CAGR of 6.6% during the forecast period 2025–2034. While late-stage and in-house activity lead today, the fastest-growing segments point to early-stage research, real-world data, rare disease programs, and outsourcing. This article highlights those areas for B2B stakeholders in the neurology clinical trials market.

Early-Stage Research Accelerates

The phase I segment is anticipated to register the highest growth rate during the forecast period. These trials are the first step in testing a new drug in humans, focusing on safety, dosage, and how the drug works in the body. Rapid growth is linked to more early-stage research and development for new neurology treatments, especially those using advanced technologies such as gene therapy and stem cell therapy. As more innovative therapies enter development pipelines, the number of initial safety and dosage studies is expected to increase.

Real-World Evidence and Rare Disease Focus

The observational studies segment is anticipated to register the highest growth rate by study design. These studies track patient health over time without a specific intervention, giving researchers a deeper understanding of how neurological conditions progress and how existing treatments perform in a natural setting. Digital health tools such as remote monitoring and patient registries make it easier to collect large amounts of long-term data, which helps shape future trial designs.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/neurology-clinical-trials-market

By indication, the amyotrophic lateral sclerosis segment is anticipated to register the highest growth rate. Growth is linked to interest in gene and cell therapies for conditions that currently have no cure. Although these trials involve a smaller group of people, the urgency to find treatments for the disease is driving quick growth in amyotrophic lateral sclerosis research.

Outsourcing to CROs

The CROs segment is anticipated to register the highest growth rate by value chain, owing to a rising trend of outsourcing trial activities to specialized contract research organizations. Companies, both large and small, turn to CROs to save costs, increase efficiency, and gain access to a wider range of services, from patient recruitment to full-scale trial management. CROs can also help companies navigate regulatory systems in different countries, which is important for large global trials. CROs and clinical trial networks are expanding service capabilities to manage the complexities of neurology trials, including wearables, remote assessments, advanced neuroimaging, eConsent, and virtual cognitive testing.

Technology and Decentralization

Clinical trial technology neurology clinical trials is changing how studies are done. Wearable devices and remote monitoring platforms make it easier for patients to participate from home, helping recruitment and retention for conditions that make travel difficult. Decentralized trial frameworks and wearable cognitive testing solutions support accessibility and adherence, and these approaches make trials more flexible and accessible to a wider group of people. Adaptive designs and patient-centric tools are also improving trial efficiency and enabling recruitment for rare and progressive neurological conditions.

AI helps extract patterns from EEG, neuroimaging, and behavioral data that are difficult to interpret manually, identifies eligible patients from real-world data, and speeds recruitment. Many pharma companies are partnering with AI startups to focus on late-stage assets with better predictive modeling.

Regional Expansion and Tariffs

Asia Pacific, Eastern Europe, and Latin America are gaining importance owing to large patient populations, cost advantages, and favorable regulatory environments. U.S. tariffs have indirectly driven up costs and disrupted supply chains for laboratory instruments, imaging technologies, and biologics, leading some organizations to relocate trial activities and turn to local sourcing, nearshoring, and digital platforms. In September 2024, Thermo Fisher's PPD business announced an expansion of bioanalytical laboratory services in Europe. Key players include IQVIA, ICON plc, Syneos Health, Parexel, Medpace Holdings, Inc., Biogen, Pfizer Inc., and Eisai Co., Ltd. Sponsors are partnering with local CROs and deploying multilingual digital solutions in emerging region

More Trending Latest Reports By Polaris Market Research:

quick-service-restaurants-qsr-market

data-center-switch-market

exosomes-market

nonlinear-optical-crystals-market

aerogel-market

dupixent-market

fire-resistant-fabrics-market

us-c4isr-market

fuel-additives-market